Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GMED 
Globus Medical (GMED)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: GMED (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
14 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $85.17
Year Target Price $85.17
| 4 | Strong Buy |
| 5 | Buy |
| 5 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 21.03% | Avg. Invested days 52 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.93B USD | Price to earnings Ratio 43.73 | 1Y Target Price 85.17 |
Price to earnings Ratio 43.73 | 1Y Target Price 85.17 | ||
Volume (30-day avg) - | Beta 1.21 | 52 Weeks Range 54.48 - 94.93 | Updated Date 06/30/2025 |
52 Weeks Range 54.48 - 94.93 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.34 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.39% | Operating Margin (TTM) 16.4% |
Management Effectiveness
Return on Assets (TTM) 5.9% | Return on Equity (TTM) 4.63% |
Valuation
Trailing PE 43.73 | Forward PE 18.8 | Enterprise Value 7564278257 | Price to Sales(TTM) 3.16 |
Enterprise Value 7564278257 | Price to Sales(TTM) 3.16 | ||
Enterprise Value to Revenue 3.01 | Enterprise Value to EBITDA 13.68 | Shares Outstanding 112949000 | Shares Floating 112053507 |
Shares Outstanding 112949000 | Shares Floating 112053507 | ||
Percent Insiders 0.69 | Percent Institutions 100.72 |
Analyst Ratings
Rating 3.93 | Target Price 85.17 | Buy 5 | Strong Buy 4 |
Buy 5 | Strong Buy 4 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Globus Medical
Company Overview
History and Background
Globus Medical was founded in 2003 by David Paul, focusing on innovative spinal implant solutions. It grew rapidly through organic expansion and strategic acquisitions, becoming a major player in the musculoskeletal solutions market.
Core Business Areas
- Spinal Implants: Development, manufacturing, and commercialization of spinal implants used in surgical procedures to correct spinal deformities, treat degenerative conditions, and stabilize the spine following trauma.
- Trauma: Development, manufacturing, and commercialization of trauma-related implants and instruments used in surgical procedures to correct bone fractures and other trauma-related injuries.
- Enabling Technologies: Robotics, navigation, and imaging systems designed to enhance surgical precision, improve clinical outcomes, and streamline surgical workflows. This segment is currently driving a significant portion of Globus Medical's growth.
Leadership and Structure
The CEO is Dan Scavilla. The company operates with a functional organizational structure across its different business units, with a focus on product development, manufacturing, and sales.
Top Products and Market Share
Key Offerings
- CREOu00ae MIS Pedicle Screw System: A minimally invasive pedicle screw system used in spinal fusion procedures. Competitors include Medtronic, Stryker, and DePuy Synthes. Estimated revenue contribution is significant but not publicly broken out.
- EXCELSIUSu2122 GPS Surgical Robot: A surgical robot used for precise placement of spinal implants. This system has gained significant traction in the market. Competitors include Medtronic's Mazor X Stealth Edition and Stryker's Mako System. No specific market share data available, but sales are increasing.
- SI-LOCu2122 Sacroiliac Joint Fusion System: Sacroiliac joint fusion system used to address SI joint dysfunction and pain. Competitors include SI-BONE and Medtronic. No specific market share data available.
Market Dynamics
Industry Overview
The musculoskeletal solutions market is characterized by technological innovation, an aging population, and increasing demand for minimally invasive surgical procedures. It is a highly competitive market with established players and emerging entrants.
Positioning
Globus Medical is positioned as a technology-driven innovator focused on providing comprehensive solutions for spinal and orthopedic disorders. Its competitive advantages include its vertically integrated manufacturing, robust product pipeline, and growing presence in enabling technologies.
Total Addressable Market (TAM)
The global spine surgery market is projected to reach $16.7 billion by 2027. Globus Medical is strategically positioned to capture a significant share of this TAM through its innovative products and enabling technologies.
Upturn SWOT Analysis
Strengths
- Vertically integrated manufacturing
- Strong product pipeline
- Growing presence in enabling technologies (robotics)
- Excellent sales growth
- Innovative products
Weaknesses
- Reliance on spinal implants as a core revenue driver
- High R&D expenses
- Integration risks associated with acquisitions
- Competitive market pressures
Opportunities
- Expansion into new geographic markets
- Increased adoption of enabling technologies
- Development of new products and therapies
- Strategic partnerships and acquisitions
- Growth in outpatient surgical procedures
Threats
- Pricing pressures from competitors
- Regulatory changes
- Product liability lawsuits
- Economic downturns
- Reimbursement challenges from healthcare providers
Competitors and Market Share
Key Competitors
- MDT
- JNJ
- STRY
Competitive Landscape
Globus Medical competes with larger, established players in the musculoskeletal solutions market. Its advantages include its focus on innovation and vertically integrated manufacturing, which allows for greater control over product quality and costs. However, it faces challenges in terms of brand recognition and financial resources compared to its larger competitors.
Major Acquisitions
Quandary Medical LLC
- Year: 2018
- Acquisition Price (USD millions): 37
- Strategic Rationale: This acquisition expanded Globus Medical's product portfolio in the interventional pain management market.
EBI, LLC
- Year: 2024
- Acquisition Price (USD millions): 374
- Strategic Rationale: The combination with EBI, LLC creates a broader portfolio of biologics products, a more extensive distribution network, and expands our presence in key segments of the orthopedics market
Growth Trajectory and Initiatives
Historical Growth: Globus Medical has experienced substantial growth in revenue and earnings over the past decade, driven by product innovation and market expansion.
Future Projections: Analysts project continued growth for Globus Medical, driven by the increasing adoption of enabling technologies and expansion into new markets.
Recent Initiatives: Recent initiatives include the launch of new surgical robotics platforms, strategic acquisitions to expand product portfolio, and investments in R&D.
Summary
Globus Medical is a technology-driven company with strong growth potential. Its enabling technologies and spinal implant offerings are compelling. However, it faces stiff competition and must manage integration risks of acquisitions. Strategic execution and market expansion will be critical for continued success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
- Globus Medical Investor Relations
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Globus Medical
Exchange NYSE | Headquaters Audubon, PA, United States | ||
IPO Launch date 2012-08-03 | President, CEO & Director Mr. Daniel T. Scavilla | ||
Sector Healthcare | Industry Medical Devices | Full time employees 5300 | Website https://www.globusmedical.com |
Full time employees 5300 | Website https://www.globusmedical.com | ||
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.